During the past decade, Investigational Drug Services conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 5 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Investigational Drug Services" #1 collaborator was "Medivation, Inc." with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Myriad Genetic Laboratories, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Investigational Drug Services" are "Breast Neoplasms" (2 trials), "Advanced or Recurrent Solid Tumors" (1 trials), "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer" (1 trials), "BRCA 1 Gene Mutation" (1 trials) and "BRCA 2 Gene Mutation" (1 trials). Many other conditions were trialed in "Investigational Drug Services" in a lesser frequency.

Most popular intervention types in "Investigational Drug Services" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Enzalutamide" (2 trials), "PF-04236921" (1 trials), "Placebo (for enzalutamide)" (1 trials), "Talazoparib" (1 trials) and "exemestane" (1 trials). Other intervention names were less common.

The vast majority of trials in "Investigational Drug Services" are 3 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Investigational Drug Services". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Investigational Drug Services, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Investigational Drug Services, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".